Radiological Physics and Technology, published by SPRINGER JAPAN KK, is a prominent journal that serves as a crucial resource in the multidisciplinary fields of medicine and radiation sciences. With an ISSN of 1865-0333 and an E-ISSN of 1865-0341, the journal has been converging impactful research from 2008 to 2024. It holds a commendable position in academic rankings, currently classified in Q2 in Physical Therapy, Sports Therapy and Rehabilitation and Radiation, along with Q3 for Medicine (miscellaneous) and Radiology, Nuclear Medicine and Imaging. The journal is well-regarded in the academic community, reflected in its Scopus rankings that place it in the upper tiers of its respective categories. Although it currently does not offer Open Access, Radiological Physics and Technology remains a pivotal publication for researchers, academics, and practitioners seeking to advance knowledge and foster innovation in radiological science. Its commitment to disseminating high-quality research ensures its continued relevance and importance within these fields.

PROSTATE CANCER AND PROSTATIC DISEASES, published by SpringerNature, is a prestigious international journal dedicated to advancing knowledge in the fields of cancer research, oncology, and urology, as evidenced by its Q1 rankings in 2023. Established in 1997, this journal has become a vital resource for researchers, clinicians, and healthcare professionals, offering impactful research and clinical insights on prostate health and disease. With its focus on innovative studies and comprehensive reviews, it addresses critical challenges in the management and treatment of prostate cancer, driving improvements in patient care globally. The journal's standing is further supported by its impressive Scopus rankings, placing it in the top tier of its categories. Readers can access high-quality, peer-reviewed articles that contribute significantly to ongoing medical practices and improve therapeutic strategies for prostate-related health issues.

The International Journal of Radiation Research, published by the IJRR-IRANIAN JOURNAL RADIATION RES, serves as a critical platform for researchers and professionals in the fields of radiology, nuclear medicine, and imaging technology. Since its inception in 2003, this peer-reviewed, open-access journal has focused on disseminating significant findings and advancements, contributing to the global discourse on radiation research. With an ISSN of 2322-3243, the journal offers valuable insights into emerging technologies and methodologies, maintaining a commitment to enhancing the understanding and application of radiation in medical science. Although currently positioned in the Q4 category across its scopes, the journal strives to elevate its impact by promoting high-quality research and innovative practices. The journal is accessible to a wide audience and encourages submissions from scholars worldwide, directly supporting the advancement of knowledge in radiological and ultrasound technology. For those seeking to explore and contribute to this dynamic field, the International Journal of Radiation Research represents an invaluable resource.

Radiotherapy and Oncology is a leading peer-reviewed journal published by Elsevier Ireland Ltd, focusing on the vital fields of hematology, oncology, and radiology. With an impressive impact factor and ranking in the top quartiles (Q1) of its categories as of 2023, it is recognized for disseminating high-quality research that contributes significantly to advancements in cancer treatment and patient care. The journal, which has been in circulation since 1983, aims to provide a platform for original research articles, reviews, and clinical studies that explore the latest innovations in radiotherapeutic technologies and oncology practices. This journal is essential for researchers, healthcare professionals, and students who are dedicated to improving cancer therapies and outcomes. Although it does not offer open access, the wealth of information contained within its pages supports continued education and development in these crucial medical fields.

Physica Medica - European Journal of Medical Physics is a premier peer-reviewed journal published by ELSEVIER SCI LTD, dedicated to advancing the field of medical physics. Established in 1989 and serving as a critical platform for innovative research, this journal covers a broad spectrum of topics within biophysics, radiology, and imaging sciences, consistently ranked in the Q1 category across these disciplines. With an impressive impact factor that highlights its influence within the scientific community—ranking 52/333 in Radiology, 42/243 in Physics and Astronomy, and 35/152 in Biochemistry—the journal is a valuable resource for professionals, researchers, and students aiming to contribute to the technological and methodological advancements in medical physics. Physica Medica is committed to fostering open dialogue and collaboration within the global medical physics community, although it currently does not offer open access options. The journal's extensive citation history and ongoing relevance underscore its importance in the continuous evolution of medical science.

Turk Onkoloji Dergisi - Turkish Journal of Oncology, published by KARE PUBL, serves as a vital platform in the field of oncology, specifically catering to the Turkish-speaking research community and contributing to global discourse. With an ISSN of 1300-7467, this journal, which has been in circulation since 2007 and continues until 2024, recognizes the importance of advancing medical knowledge in cancer research through rigorous peer-reviewed articles. Although currently positioned in the Q4 category of oncology journals with a Scopus rank of #344 out of 404, the journal is dedicated to fostering significant research insights and innovative perspectives on cancer treatment and prevention. While it does not currently offer open access, its content is essential for professionals, researchers, and students aiming to enhance their understanding of oncology developments in Turkey and beyond. The Turkish Journal of Oncology not only aspires to improve the quality of cancer care but also strives to enhance collaboration among researchers, thereby influencing future oncology practices.

International Journal of Radiation Oncology Biology Physics, published by Elsevier Science Inc, is a premier academic journal that has played a critical role in advancing the field of radiation oncology since its inception in 1975. With an impressive impact factor and recognition as a Q1 journal across multiple categories such as Cancer Research, Oncology, and Radiology, this journal serves as a vital resource for researchers, clinicians, and students dedicated to understanding and improving cancer treatment modalities. Its multifaceted scope encompasses original research, reviews, and innovative clinical studies, fostering a deeper understanding of the interplay between radiation, biology, and oncology. With a remarkable ranking in Scopus, including a top position in Radiation Physics and an elite percentile in Oncology, IJROBP remains at the forefront of scientific discovery and innovation in the management of cancer. A traditional subscription model ensures high-quality, peer-reviewed content, providing invaluable insights that continue to advance the standards of care and research in radiation oncology.

SEMINARS IN RADIATION ONCOLOGY is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, dedicated to advancing the field of radiation oncology through high-quality research and comprehensive reviews. With an impressive impact factor and a notable HIndex, this journal holds a prominent place within the academic community, particularly illustrated by its Q2 ranking in both Cancer Research and Oncology, and a Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. Since its inception in 1991, the journal has served as a vital resource for researchers, clinicians, and healthcare professionals, facilitating the exchange of innovative ideas and practices that shape the future of cancer treatment. While the journal is not open access, it offers essential insights into the latest advancements in the field, catering to a diverse audience eager to expand their knowledge and improve patient outcomes in the realm of radiation therapy.

Translational Oncology is a premier open access journal published by Elsevier Science Inc, dedicated to the rapidly evolving field of cancer research and oncology. Since its inception in 2008, the journal has been a vital platform for the dissemination of innovative research and findings that bridge the gap between laboratory discoveries and clinical applications. With an impressive impact factor and ranked Q2 in Cancer Research and Q1 in Oncology, it occupies a prominent position in the academic landscape, helping to shape the future of cancer therapeutics and patient care. The journal offers valuable insights across a diverse array of topics, including molecular biology, genetic factors in cancer, and innovative treatment strategies, ensuring relevance and engagement for its readership. As it converges toward 2024, Translational Oncology continues to attract a global audience of researchers, healthcare professionals, and students committed to advancing our understanding of cancer and enhancing clinical outcomes.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.